|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We found the frequency of GSTT1 null genotype of 19.2% in cases and 15.7% in controls, with an adjusted odds ratio (OR) of 1.4 (95% confidence interval (CI), 0.70-2.81), and a frequency of GSTM1 null genotype of 59% in cases with oxyphilic tumors and of 55.6% in controls (OR 1.24; 95% CI, 0.62-2.48), indicating that the GSTT1 and M1 null genotypes do not increase the risk of development of oxyphilic tumors.
|
16427734 |
2006 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
GSTT1 deletion was nearly significantly more common among glioblastoma cases with tumor p53 mutation than for those whose tumors did not have p53 mutation (OR 2.8; 95% CI 0.93-8.4; P = 0.07).
|
15006924 |
2004 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The GSTM1 and GSTT1 genotypes did not show any correlation with the risk of the de novo diagnosed neoplasms.
|
15382272 |
2004 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
It is suggested that the GSTT1 polymorphism may have an impact on the severity of the tumor and its location.
|
30106268 |
2018 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Furthermore, NAT2 slow-acetylator, GSTM1 null, and GSTM1/GSTT1-double null genotypes were associated with higher tumor grade (P=0.001, 0.022, and 0.036, respectively), and only NAT2 slow-acetylator genotype was associated with higher tumor stage (P=0.007).
|
19303722 |
2009 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
More than one tumour at first presentation (P <0.0001, hazard ratio 2.72) and GSTT1 null (P = 0.028, hazard ratio 1.74) were associated with decreased time to next primary tumour presentation.
|
9276622 |
1997 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We conclude that the GSTP1 and GSTT1 genes could play a role in carcinogenesis in the breast, possibly through increased frequency of mutations in tumor suppressor genes such as p53.
|
11700265 |
2001 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We conclude that patients with carcinoma of the breast and inheritance of a combined gene deletion of GSTM1 and GSTT1 might bear an increased risk to develop a secondary therapy-induced hematologic neoplasia.
|
11792413 |
2002 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A significantly lower frequency of GSTT1 deletion in glioma patients compared to healthy controls indicates that GSTT1 deletion may exert a protective role against gliomagenesis, influence therapeutic response to intranasal perillyl alcohol treatment, and increase overall survival, especially considering tumor topography.
|
23765968 |
2013 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A case control association study was carried out to investigate polymorphisms in genes CYP1A1 (3801T > C), GSTM1, and GSTT1 (null genotypes) and oral squamous cell carcinoma (OSCC), including a correlation with some histopathological findings (tumor size, lymph node invasion and degree of tumor differentiation).
|
18507050 |
2008 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Both GSTM1*0 (16/26 (61%) versus 10/40 (25%); p=0.003, OR 5; 95% CI=2-14) and GSTT1*0 (12/26 (46%) versus 13/40 (33%); p=0.2, OR 2; 95% CI=0.6-5) were associated with a higher risk of diffuse tumor than of intestinal tumor.
|
18365908 |
2008 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Here, we have investigated the association of tobacco - betel quid chewing, HPV infection, GSTM1-GSTT1 null genotypes, and tumour stages with mitochondrial DNA (mtDNA) content variation in oral cancer patients.
|
23469236 |
2013 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Similarly, no significant differences were obtained if GSTT1 and/or GSTM1 null genotypes were analyzed in subgroups of control subjects and ovarian cancer patients between the ages of 20-40, 41-70 and 71-90 years and in individuals with a positive family history of neoplastic disease.
|
9751255 |
1998 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Thus, logistic regression analysis adjusted by tumor size revealed a positive association between GSTT1 deletion and recurrence risk in general BC (OR 4.25; p = 0.04), while GSTM1 was negatively associated with recurrence risk in ER/PR<sup>+</sup>HER2<sup>-</sup> samples (OR 0.07; p = 0.03).
|
28455582 |
2018 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
After stratification based on the tumor stage and grade, the high-risk group (T1G3) with a GSTT1-positive genotype showed a 14-fold higher risk of early BCG failure compared with those with a GSTT1-null genotype.
|
24411789 |
2014 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
On the other hand, the combined null genotype of GSTM1 and GSTT1 was associated with proximal tumors.
|
9834266 |
1998 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In GSTM1-GSTT1 interaction analysis, individuals with dual null genotype were associated with a significantly increased risk of cervical neoplasia (OR = 1.72; 95%CI, 1.18-2.51).
|
21629772 |
2011 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Patients with GSTT1 deletion had tumors of more advanced stages, and those with Val432 polymorphism in CYP1B1 had tumors of higher Fuhrman grade.
|
21458313 |
2013 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In this study we investigate the association of A313G and C341T GSTP1 polymorphisms, GSTM1 and GSTT1 null genotypes in the head and neck cancer development, interactions between these polymorphisms,the tumor histopathologic parameters and risk factors (smoking and drinking) were also evaluated in the case-control study.
|
23661016 |
2013 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Among the patients with oligodendroglial tumors (n = 94), patients who had the GSTT1 null genotype had a 2.9 times increased risk of death (95% confidence interval [CI], 1.3-6.3) compared with patients who had the GSTT1 non-null genotype.
|
20187096 |
2010 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We found that African-Americans with the GSTT1 null genotype had increased BCR risk compared to those having GSTT1 present (hazard ratio (HR) = 2.30; 95% CI = 1.01–5.18; p = 0.04); and African-Americans with the GSTT1 null genotype and high grade tumors had an even greater risk (HR = 7.82; 95% CI = 2.49–24.50; p < 0.001).
|
19568698 |
2009 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The longitudinal study showed, after adjustment for age and tumour number at presentation, that GSTT1 null (P < 0.001, rate ratio 2.677) and CYP2D6 EM (P < 0.001, rate ratio 2.154) were significant determinants of accrual while CYP1A1 Ile/Ile was associated with slower accrual than the Ile/Val and Val/Val genotypes (P = 0.008, rate ratio 0.690).
|
8824510 |
1996 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The results obtained showed that the presence of three potentially risk alleles (GSTM1 null, GSTT1 null, and GSTP1 Ile/Ile) lead to a significant OR increase for all the cases, irrespective of the type of tumor (OR=2.91), for papillary (OR=3.64) but not for follicular tumors.
|
15120911 |
2004 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In a multivariate analysis, the effects of GSTM1 null/GSTT1 null on survival were lost when residual disease and tumor grade were included.
|
11328408 |
2001 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This meta-analysis suggests that GSTM1 null and GSTT1/GSTM1 double null polymorphisms might be significantly associated with an increased tumor response.
|
26577857 |
2016 |